US EditionPublished • loading... • Updated
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics granted 6,000 stock options to a new employee as an inducement under NYSE rules to motivate high performance and long-term contribution.
- On Jan. 2, 2026, ADC Therapeutics SA granted options to purchase 6,000 common shares to a new employee, the company said.
- The Compensation Committee of ADC Therapeutics' Board of Directors approved the option grant pursuant to the Company's Inducement Plan as a material inducement under NYSE Listed Company Manual Rule 303A.08.
- The award vests 25% on the first anniversary and thereafter monthly, fully vesting at the fourth anniversary subject to continued employment with the Company.
- The company disclosed the grant via a press release filed under NYSE Rule 303A.08, signaling use of the Inducement Plan to attract talent at a commercial‑stage biotech known for ZYNLONTA and ADC programs.
- Against a backdrop of strategic restructuring and program timelines, the inducement supports hiring as ADC Therapeutics advances LOTIS‑7, commercializes ZYNLONTA, and develops a PSMA‑targeting ADC.
Insights by Ground AI
47 Articles
47 Articles
LoudounTimes.com+45 Reposted by 45 other sources
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an…
Coverage Details
Total News Sources47
Leaning Left6Leaning Right7Center15Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 21%
C 54%
R 25%
Factuality
To view factuality data please Upgrade to Premium
